1441 Eastlake Ave
Los Angeles, CA 90089
United States
Refractory metastatic colorectal cancer, Regorafenib, Dose-optimization, Phase 2, Dosing strategies
BMAL1; REVERBA; circadian rhythm; bevacizumab; colorectal cancer